Cereno Scientific reports progress with its CS1 Phase II study in PAH: all study sites are activated and top-line results are expected end of 2023
Cereno Scientific (XSAT: CRNO B) today announced that all clinical sites are activated and actively recruiting patients in the ongoing Phase II study in the rare disease pulmonary arterial hypertension (PAH) with the drug candidate CS1. To date, three patients have been randomized and entered the treatment period. The study’s top-line results are now expected by end of 2023.“It is great to finally see all 9 clinical sites in the study activated in January and recruiting after an unforeseen extended start-up and activation phase. As previously communicated, during fall and winter we worked